Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2008-04-29
2008-04-29
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S080000, C514S690000, C514S659000, C424S049000
Reexamination Certificate
active
10731769
ABSTRACT:
Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
REFERENCES:
patent: 4820734 (1989-04-01), Bernauer et al.
patent: 6136595 (2000-10-01), Ihle et al.
patent: 6177433 (2001-01-01), Uckun et al.
patent: 2002/0032204 (2002-03-01), Moon et al.
patent: 2002/0042513 (2002-04-01), Uckun et al.
patent: 2003/0013728 (2003-01-01), Uckun
patent: 712187 (1965-06-01), None
patent: 1466205 (1960-04-01), None
patent: 0242489 (2002-05-01), None
Database EMBASE on STN Online, No. 2003366614, Kahan et al. New Approaches of Transplant Immunosuppression, abstract, Transplantation Proceedings, 2003, 35/5, pp. 1621-1623.
Database EMBASE on STN Online, No. 2003391451, Manez, R. ‘Current Trends in Transplantation and Immunosuppressive Treatment,’ abstract, Drug News and Perspective, 2003, 16/5, pp. 332-336.
Database CAPLUS on STN Online, No. 1993:603032, Dimmock et al. Evaluation of Some Mannich Bases of Cycloalkanones and Related Compounds For Cytotoxic Activity, abstract, European Journal of Medicinal Chemistry, 1993, 28(4), pp. 313-322.
Database CAPLUS on STN Online, No. 1995:962281, Dimmock et al. ‘Synthesis and Cytotoxic Evaluation of Some Mannich Bases of Alicyclic Ketones,’ abstract, Pharmazie, 1995, 50(1), pp. 668-671.
Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol. (2000) 12:242-249.
Denton, MD, et al., Immunosuppressive strategies in transplantation. Lancet (1999) 353:1083-1091.
Mihatsch MJ, et al. The side effects of Ciclosporin-A and Tacrolimus. (1998) Clin. Nephrol 49 (6):356-363.
Kirken RA, Stepkowski SM. New directions in T-cell signal transduction and transplantation tolerance. Curr Opin in Organ Transplant (2002) 7:18-25.
Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. (1994) 76:263-274.
Irving BA, et al. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med. (1993) 177:1093-1103.
Chan AC, et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science. (1994) 264:1599-1601.
Appleby MW, et al. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell. (1992) 70:751-763.
Kuo CT, Leiden JM. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol. (1999) 17:149-187.
Leonard WJ, O'Shea JJ. JAKs and STATs: biological implications. Annu Rev Immunol. (1998);16:293-322.
Kondo M, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. (1993) 262:1874-1877.
Noguchi M, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. (1993);262:1877-1880.
Russell SM, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science. (1994) 266:1042-1045.
Malabarba MG, et al. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J. (1996) 319:865-872.
Szabo SJ, et al. Genes that regulate interleukin-4 expression in T cells, Curr Opin Immunol. (1997) 9:776-781.
Kirken RA, et al. Identification of Interluekin-2 Receptor-associated Tyrosine Kinase p116 as Novel Leukocyte-specific Janus Kinase. J Biol Chem (1994) 269(29):19136-19141.
Thomis TC, Berg LJ. Peripheral Expression of Jak3 Is Required to Maintain T Lymphocyte Function. J. Exp. Med. (1997) 185(2):197-206.
Kirken RA, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T-cells. J Leukoc Biol (1999) 65:891-899.
Behbod F, et al. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol (2001) 166:3724-3732.
Stepkowski SM, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood (2002) 99:680-689.
Yamashita H, et al. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem. (1998) 273(46):30218-30224.
Kirken RA, et al. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Cytokine. (1995) 7(7):689-700.
Winters GL, et al. The international society for heart and lung transplantation grading system for heart transplant biopsy specimens: Clarification and commentary. J Heart Lung Transplant. 1998; 17:754-760.
Dimmock JR, Kumar P. Anticancer and Cytotoxic Properties of Mannich Bases. Current Medicinal Chemistry (1997) 4:1-22.
Dimmock JR, et al. Synthesis and Cytotoxic Evaluation of Some Mannich Bases of Alicyclic Ketones. Pharmazie (1995) 50:668-671.
Kirken RA. Targeting JAK3 for Immune Suppression and Allograft Acceptance. Transplantation Proc, (2001) 33:3268-3270.
Stepkowski, Stanislaw M. et al., “Selective Inhibitor Of Janus Tyrosine Kinase 3, PNU156804, Prolongs Allograft Survival And Acts Synergistically With Cyclosporine But Additively With Rapamycin,” Blood, vol. 99, No. 2, Feb. 15, 2002, pp. 680-689.
Supplementary European Search Report for EP Application No. 03796805, Date of Completion Mar. 20, 2007, The Hague, 2 pgs.
Fokt Izabela
Kahan Barry D.
Kirken Robert A.
Kosinski Szymon
Priebe Waldemar
Board of Regents , The University of Texas System
Conley & Rose, P.C.
Kwon Brian
LandOfFree
Methods for selectively inhibiting Janus tyrosine kinase 3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for selectively inhibiting Janus tyrosine kinase 3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for selectively inhibiting Janus tyrosine kinase 3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3942117